Therapeutic potentials of angiostatin in the treatment of cancer.
The discovery of specific endothelial inhibitors such as angiostatin and endostatin not only increases our understanding of the functions of these molecules in the regulation of physiological and pathological angiogenesis, but also provides an important therapeutic strategy for cancer treatment. Recent studies have demonstrated that the angiostatin protein significantly suppresses the growth of a variety of tumors in mice. However, the dosages of angiostatin protein used in these animal studies seem to be too high for clinical trials. In addition, repeated injections and long-term treatment with angiostatin are required to reach its maximal antitumor effect. In this article, I will discuss several alternative approaches that may become feasible to move angiostatin therapy from animal experiments into the clinic. In particular, I will emphasize the therapeutic potentials of angiostatin gene therapy and more potent angiogenesis inhibitors that are related to angiostatin.
Cao
Y
Y
Laboratory of Angiogenesis Research, Microbiology and Tumor Biology Center, Karolinska Institute, S-171 77, Stockholm, Sweden. yihai.cao@mtc.ki.se
D043168:Angiostatins; D000818:Animals; D015316:Genetic Therapy; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000235:genetics / Q000628:therapy*; D009374:Neoplasms, Experimental / Q000235:genetics / Q000628:therapy*; D009389:Neovascularization, Pathologic / Q000235:genetics / Q000628:therapy*; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use*; D010958:Plasminogen / Q000008:administration & dosage / Q000627:therapeutic use*
D010446:Peptide Fragments; D043168:Angiostatins; D010958:Plasminogen